Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.

Brand K, Landry D, Mulhern J, Braden G

BMC nephrology7 Apr 2025

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 48-year-old man with hyperkalemic periodic paralysis, muscle strength returned to levels not seen in decades over the year after semaglutide started.

    In plain wordsIn one man with a muscle disorder, strength returned over the next year after he started semaglutide.

    Outcome
    IncreaseMuscle strength
    Study

    n = 1

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Over the next year his strength and quality of life returned to levels he had not had in decades.
    3 context sentences
    Summary · context
    Before the semaglutide he could not rise out of a chair without help and his gait was very slow.
    Summary · context
    The patient is a 48 year old man with hyperPP from a familial autosomal dominant sodium channel point mutation in the SCN4A gene at position 704 with a Threonine to Methionine substitution that lead to symptoms starting in early childhood.
    Summary · context
    In the spring of 2023, semaglutide was initiated for weight loss.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 48-year-old man with hyperkalemic periodic paralysis, quality of life returned to levels not seen in decades over the year after semaglutide started.

    In plain wordsIn one man with a muscle disorder, quality of life improved over the next year after he started semaglutide.

    Outcome
    IncreaseQuality of life
    Study

    n = 1

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Over the next year his strength and quality of life returned to levels he had not had in decades.
    3 context sentences
    Summary · context
    Before the semaglutide he could not rise out of a chair without help and his gait was very slow.
    Summary · context
    The patient is a 48 year old man with hyperPP from a familial autosomal dominant sodium channel point mutation in the SCN4A gene at position 704 with a Threonine to Methionine substitution that lead to symptoms starting in early childhood.
    Summary · context
    In the spring of 2023, semaglutide was initiated for weight loss.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.